Press release
Migraine Market to Exhibit Rapid Growth Rate During the Forecast Period (2024-2034), Investigates DelveInsight | Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, Teva Branded Pharmaceutical, AbbVie
DelveInsight's "Migraine Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the Migraine market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Migraine market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Migraine Market Forecast
https://www.delveinsight.com/sample-request/migraine-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Migraine Market Report:
• The Migraine market size was valued approximately USD 10,880 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In 2023, the United States had the largest market size for migraine within the 7MM, amounting to roughly USD 6,790 million, and this figure is projected to rise by 2034.
• In 2023, the market size for episodic migraine (including preventive and acute treatments) in the US was approximately USD 4,026 million, while for chronic migraine (including preventive and acute treatments), it was nearly USD 2,766 million in the same year.
• In 2023, the United States represented the largest proportion of migraine patients within the 7MM, comprising 39% of the total, followed by Japan with approximately 14% of the total cases. Among European nations, the UK had the highest number of cases, accounting for around 11% of the total cases within the 7MM.
• In 2023, the total prevalent population of migraine across the 7MM was estimated to be approximately 119,233 cases.
• The total prevalent cases of migraine in the United States are anticipated to undergo substantial growth with a significant compound annual growth rate (CAGR) by 2034, starting from approximately 46,140 cases in 2023.
• DelveInsight's analysts indicate that the majority of migraine cases are observed in females compared to males. In 2023, there were approximately 11,535k male cases and 34,605k female cases of migraine in the US.
• In EU4 and the UK, the majority of diagnosed migraine cases in 2023 were classified as Episodic Migraine, totaling approximately 15,839k cases. Conversely, Chronic Migraine accounted for the fewest cases, with around 2,411k cases in the same year.
• Key Migraine Companies: Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories, Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, AbbVie, Tian Medical Inc., Allergan, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others
• Key Migraine Therapies: AXS-07, ABP-450, Aimovig, CL-H1T, AIMOVIG, Fremanezumab, propranolol LA, LBR-101, Atogepant, Galcanezumab, Marcaine, Atogepant, Galcanezumab, Eptinezumab, TNX-1900, IONIS-PKKRx (ISIS 546254), and others
• The Migraine epidemiology based on gender analyzed that females experience a more significant impact in relation to Migraine compared to males
• The Migraine market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Migraine pipeline products will significantly revolutionize the Migraine market dynamics.
Migraine Overview
Migraine, a main headache illness, is a neurological condition that commonly manifests as severe, incapacitating headaches among other symptoms. It affects all ages and frequently runs in families. There are primarily two types: acute migraine and Migraine.
Get a Free sample for the Migraine Market Report:
https://www.delveinsight.com/report-store/migraine-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Migraine Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Migraine Epidemiology Segmentation:
The Migraine market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Migraine
• Prevalent Cases of Migraine by severity
• Gender-specific Prevalence of Migraine
• Diagnosed Cases of Episodic and Chronic Migraine
Download the report to understand which factors are driving Migraine epidemiology trends @ Migraine Epidemiology Forecast
https://www.delveinsight.com/sample-request/migraine-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Migraine Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Migraine market or expected to get launched during the study period. The analysis covers Migraine market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Migraine Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Migraine Therapies and Key Companies
• AXS-07: Axsome Therapeutics
• ABP-450: AEON Biopharma, Inc.
• Aimovig: Amgen
• CL-H1T: Charleston Laboratories
• AIMOVIG: Amgen
• Fremanezumab: Teva Pharmaceuticals
• Galcanezumab: Eli Lilly and Company
• propranolol LA: Anne Lindblad
• Atogepant: Allergan
• LBR-101: Teva Branded Pharmaceutical
• Atogepant: AbbVie
• Galcanezumab: Eli Lilly and Company
• Marcaine: Tian Medical Inc.
• Atogepant: Allergan
• Galcanezumab: Eli Lilly and Company
• Eptinezumab: H. Lundbeck A/S
• TNX-1900: Tonix Pharmaceuticals, Inc.
• IONIS-PKKRx (ISIS 546254): Ionis Pharmaceuticals, Inc.
Discover more about therapies set to grab major Migraine market share @ Migraine Treatment Market
https://www.delveinsight.com/sample-request/migraine-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Scope of the Migraine Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Migraine Companies: Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories, Amgen, Teva Pharma, Eli Lilly and Company, Anne Lindblad, Allergan, AbbVie, Tian Medical Inc., Allergan, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others
• Key Migraine Therapies: AXS-07, ABP-450, Aimovig, CL-H1T, AIMOVIG, Fremanezumab, propranolol LA, LBR-101, Atogepant, Galcanezumab, Marcaine, Atogepant, Galcanezumab, Eptinezumab, TNX-1900, IONIS-PKKRx (ISIS 546254), and others
• Migraine Therapeutic Assessment: Migraine current marketed and Migraine emerging therapies
• Migraine Market Dynamics: Migraine market drivers and Migraine market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Migraine Unmet Needs, KOL's views, Analyst's views, Migraine Market Access and Reimbursement
To know more about Migraine companies working in the treatment market, visit @ Migraine Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/migraine-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Migraine Market Report Introduction
2. Executive Summary for Migraine
3. SWOT analysis of Migraine
4. Migraine Patient Share (%) Overview at a Glance
5. Migraine Market Overview at a Glance
6. Migraine Disease Background and Overview
7. Migraine Epidemiology and Patient Population
8. Country-Specific Patient Population of Migraine
9. Migraine Current Treatment and Medical Practices
10. Migraine Unmet Needs
11. Migraine Emerging Therapies
12. Migraine Market Outlook
13. Country-Wise Migraine Market Analysis (2020-2034)
14. Migraine Market Access and Reimbursement of Therapies
15. Migraine Market Drivers
16. Migraine Market Barriers
17. Migraine Appendix
18. Migraine Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Migraine Pipeline https://www.delveinsight.com/report-store/migraine-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Migraine Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Migraine market. A detailed picture of the Migraine pipeline landscape is provided, which includes the disease overview and Migraine treatment guidelines.
Migraine Epidemiology https://www.delveinsight.com/report-store/migraine-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Migraine Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Migraine epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Seborrheic Dermatitis Market http://www.delveinsight.com/report-store/seborrhoeic-dermatitis-market
DelveInsight's "Seborrhoeic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Seborrhoeic Dermatitis, historical and forecasted epidemiology as well as the Seborrhoeic Dermatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hypercoagulability Market
http://www.delveinsight.com/report-store/hypercoagulability-market
DelveInsight's "Hypercoagulability- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypercoagulability, historical and forecasted epidemiology as well as the Hypercoagulability market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Orthostatic Hypotension Market http://www.delveinsight.com/report-store/orthostatic-hypotension-market
DelveInsight's "Orthostatic Hypotension Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Orthostatic Hypotension, historical and forecasted epidemiology as well as the Orthostatic Hypotension market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Point Of Care Glucose Testing Market http://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
DelveInsight's 'Point of Care Glucose Testing - Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Substance Drug Abuse Market http://www.delveinsight.com/report-store/substance-drug-abuse-market
DelveInsight's "Substance (Drug) Abuse Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance (Drug) Abuse, historical and forecasted epidemiology as well as the Substance (Drug) Abuse market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Migraine Market to Exhibit Rapid Growth Rate During the Forecast Period (2024-2034), Investigates DelveInsight | Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, Teva Branded Pharmaceutical, AbbVie here
News-ID: 3521807 • Views: …
More Releases from DelveInsight Business Research
Global Biopsy Devices Market Poised for Robust Growth, Expected to Reach USD 10. …
The global biopsy devices market is on a trajectory of strong growth, projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during the forecast period (2025-2032). This growth is being driven by the rising incidence of cancer worldwide, escalating demand for minimally invasive diagnostic procedures, continuous technological advancements, and strong product development pipelines from key market players.
Get access…
Anti-retropulsion Devices Market Size is expected to Grow at a CAGR of 6.69% by …
Anti-retropulsion Devices Market by Product Type (Stone Entrapment and Extraction Devices, Stone Retrieval Devices, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 due to the growing prevalence of kidney stones and increasing R&D activities and product launches in anti-retropulsion devices
[Albany, United States], September 2025 - The…
Acanthamoeba Keratitis Market Dynamics Indicate Upward Trajectory Through 2034, …
The Acanthamoeba Keratitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acanthamoeba Keratitis pipeline products will significantly revolutionize the Acanthamoeba Keratitis market dynamics.
DelveInsight's "Acanthamoeba Keratitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Acanthamoeba Keratitis, historical and forecasted epidemiology as well as the Acanthamoeba Keratitis market trends in the United…
Anticoagulants Market Positioned for Accelerated Development Through 2030, Delve …
DelveInsight's *Anticoagulants Market Insights, Competitive Landscape, and Market Forecast - 2030* report provides a comprehensive analysis of anticoagulants, along with historical and projected market trends worldwide, covering North America, Europe, Asia-Pacific, and the Rest of the World (RoW).
The latest healthcare forecast report provides an in-depth analysis of Anticoagulants, offering comprehensive insights into the Anticoagulants revenue trends, prevalence, and treatment landscape. The report delves into key Anticoagulants statistics, highlighting the…
More Releases for Migraine
Leading Growth Driver in the Migraine Market Share in 2025: Rising Prevalence Of …
What Market Share dynamics are playing a key role in accelerating the growth of the migraine Market Share?
The migraine Market Share is projected to grow, driven by the rising occurrence of migraines. Migraines, a kind of headache that typically affects one side of the brain and causes intense, throbbing pain or a pulsing sensation, can be managed and relief can be provided via proper treatment. This treatment paves the way…
Emerging Acute Migraine Treatment Market Trend 2025-2034: Innovative CGRP Recept …
How Is the Acute Migraine Treatment Market Projected to Grow, and What Is Its Market Size?
The market size for acute migraine treatment has witnessed substantial growth in the past few years. Forecasts expect it to expand from $2.6 billion in 2024 to $2.91 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this growth in the historical period include the rising incidence of migraines,…
Key Influencer in the Migraine Market 2025: Rising Prevalence Of Migraine Drives …
"What Is the Forecasted Market Size and Growth Rate for the Migraine Market?
The migraine market is projected to grow steadily from $1.93 billion in 2024 to $1.97 billion in 2025, at a CAGR of 2.2%. This growth is attributed to the rising prevalence of migraines, growing awareness of treatment options, government initiatives, increased alcohol consumption, and lifestyle changes.
Migraine Market: Expected to grow to $2.25 billion by 2029 at a CAGR…
How Big is Migraine Drugs Market?
In 2022, the Global Migraine Drugs Market soared to USD 10,972.1 million, marking a significant milestone. Projections indicate a promising trajectory, with expectations set for substantial growth, potentially reaching USD 26,618.96 million by 2031. Forecasts for the period between 2024 and 2031 suggest a robust Compound Annual Growth Rate (CAGR) of 12.1% for the migraine drugs market.
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive…
Migraine Therapeutics Market - Relieve the Burden: Empowering Lives through Migr …
Newark, New Castle, USA - new report, titled Migraine Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Migraine Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Migraine Therapeutics market. The report offers an overview of the market, which…
Rise in Prevalence of Migraine Drives the Migraine Drugs Market | Outlook 2025
Migraine is characterized by a recurrent throbbing headache, which affects only one side of the head. It is accompanied by vomiting, nausea and even altered vision in some cases.
The increase in the prevalence of migraine, the rapid increase in the female population and the increased awareness among patients for the treatment and prevention of migraine are driving the growth of the global market for anti-migraine drugs.
Get Access to TOC /…
